Age-Related Macular Degeneration Global Market Report 2024

Description

“Age-Related Macular Degeneration Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on age-related macular degeneration market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
Measure the impact of high global inflation on market growth.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for age-related macular degeneration? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The age-related macular degeneration market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of COVID-19 on supply chains and consumption patterns.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

1) By Type: Wet Age-Related Macular Degeneration (AMD); Dry Age-Related Macular Degeneration (AMD)
2) By Drug: Eylea; Lucentis; Avastin; Other Products
3) By Route Of Administration: Intravenous; Intravitreal
4) By Distribution Channel: Hospital Pharmacy; Specialty Pharmacy; Online Pharmacy
Companies Mentioned: F. Hoffmann-La Roche Ltd.; Novartis AG; Bayer AG; Pfizer Inc.; Bausch Health Companies Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Age-related macular degeneration (AMD) is a progressive eye condition characterized by the deterioration of the macula, located at the center of the retina, resulting in a gradual loss of central vision due to aging. Therapeutic options for AMD encompass regular eye examinations, lifestyle modifications, and specific nutritional supplements.

There are two main types of age-related macular degeneration, wet age-related macular degeneration (AMD) and dry age-related macular degeneration (AMD). Wet AMD is a progressive eye disease marked by the growth of abnormal blood vessels beneath the macula, the central part of the retina responsible for sharp, central vision. Treatment for wet AMD involves the use of various drugs such as Eylea, Lucentis, Avastin, and others. These drugs are administered through intravenous and intravitreal routes and are typically dispensed through hospital pharmacies, specialty pharmacies, and online pharmacies.

The age-related macular degeneration market research report is one of a series of new reports from The Business Research Company that provides age-related macular degeneration market statistics, including age-related macular degeneration industry global market size, regional shares, competitors with an age-related macular degeneration market share, detailed age-related macular degeneration market segments, market trends and opportunities, and any further data you may need to thrive in the age-related macular degeneration industry. This age-related macular degeneration market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The age-related macular degeneration market size has grown strongly in recent years. It will grow from $9.17 billion in 2023 to $9.9 billion in 2024 at a compound annual growth rate (CAGR) of 7.9%. The expansion observed in the historical period can be attributed to demographic shifts characterized by an aging population, evolving lifestyles influenced by environmental factors, genetic predisposition, heightened awareness leading to early diagnosis, and advancements in diagnostic techniques.

The age-related macular degeneration market size is expected to see strong growth in the next few years. It will grow to $13.1 billion in 2028 at a compound annual growth rate (CAGR) of 7.3%. The anticipated growth in the forecast period can be attributed to ongoing research in genetics and biomarkers, the emergence of novel therapeutic modalities, the increasing prominence of telemedicine and remote monitoring, as well as a focus on patient advocacy and education. Major trends expected in the forecast period include the adoption of personalized medicine approaches, innovations in retinal imaging technologies, the rise of sustained drug delivery systems, an increase in clinical trials for investigational therapies, and collaborative efforts in research and development.

The anticipated growth in the age-related macular degeneration (AMD) market is expected to be driven by the increasing prevalence of AMD, a progressive eye condition that affects the macula, a crucial part of the retina responsible for central vision. Treatments for age-related macular degeneration aim to mitigate the severity of the disease, and the rising prevalence of AMD is a significant factor contributing to market growth. According to reports from Optimaxa, a UK-based laser eye treatment specialist, as of February 2023, approximately 196 million individuals worldwide are affected by age-related macular degeneration (AMD), with projections estimating a rise to 288 million by 2040. This would account for 8.7 percent of the global population. The escalating prevalence of AMD underscores the need for effective treatments and is a key driver for the growth of the age-related macular degeneration market.

The expanding aging population is expected to contribute significantly to the growth of the age-related macular degeneration market. The aging population represents a demographic shift characterized by a higher proportion or an increasing number of individuals aged 65 years and older. As the global elderly population increases, there is a corresponding rise in the prevalence of AMD. For instance, in 2022, according to Visual Capitalist, a Canada-based company focused on creating visual content about the latest trends, there were 771 million people aged 65 years and older globally, accounting for almost 10% of the world's population. Consequently, the expanding aging population is a key factor driving the growth of the age-related macular degeneration market.

Product innovations emerge as a prominent trend in the age-related macular degeneration (AMD) market, with major companies actively developing novel products and drugs to solidify their market position. An example of this trend is evident in the actions of Genentech Inc., a leading US-based biotechnology and pharmaceutical company. In October 2021, Genentech received regulatory approval from the US Food and Drug Administration for its groundbreaking Susvimo (ranibizumab) therapy. This therapy is designed for patients suffering from wet AMD. Susvimo stands out as a sustained-release implant that delivers ranibizumab, preventing the growth of abnormal blood vessels in the retina. Notably, this innovative drug offers a more convenient and less invasive treatment option compared to traditional eye injections, marking a significant advancement in AMD treatment.

Major companies in the age-related macular degeneration market are engaging in strategic partnerships and collaborations to fortify their market presence. Strategic partnerships involve collaborative relationships formed between two or more organizations to achieve specific business objectives or goals. An illustrative case is the collaboration between Mosaic Biosciences, a US-based biotechnology company, and Ocular Therapeutix, a US-based pharmaceutical company. In June 2021, these companies entered into a research collaboration aimed at developing a drug to treat patients with dry age-related macular degeneration. This strategic partnership not only strengthens the companies' research and development portfolios but also presents a high-growth opportunity.

In May 2023, Astellas Pharma Inc., a Japan-based pharmaceutical company, acquired IVERIC Bio Inc. for $5.9 billion. Through this acquisition, Astellas Pharma aims to expand its presence in the ophthalmology market and accelerate the development of novel treatments for age-related macular degeneration. IVERIC Bio Inc., a US-based biotech corporation, specializes in the development of drugs and products for treating age-related macular degeneration, making it a strategic addition to Astellas Pharma's portfolio in the ophthalmology sector.

Major companies operating in the age-related macular degeneration market report are F. Hoffmann-La Roche Ltd., Novartis AG, Bayer AG, Pfizer Inc., Bausch Health Companies Inc., Regeneron Pharmaceuticals Inc., Amgen Inc., Alimera Sciences Inc., Alkeus Pharmaceuticals Inc., AbbVie Inc., Outlook Therapeutics Inc., Biogen Inc., Samsung Bioepis Co. Ltd., Allergan plc, Biocon Ltd., Bio-Thera Biopharmaceutical Co. Ltd., AstraZeneca plc, Acucela Inc., Ophthotech Corporation, Kodiak Sciences Inc., REGENXBIO Inc., Alkahest Inc., Opthea Limited, Apellis Pharmaceuticals Inc., Graybug Vision Inc., IVERIC bio Inc., Santen Pharmaceutical Co. Ltd., Ocular Therapeutix Inc., Tyrogenex Inc., Chengdu Kanghong Pharmaceutical Group Co. Ltd., I-Mab Biopharma Co. Ltd., pSivida Corp., Clearside Biomedical Inc., SciFluor Life Sciences LLC, Lineage Cell Therapeutics Inc.

North America was the largest region in the global age-related macular degeneration market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the age-related macular degeneration market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the age-related macular degeneration market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The age-related macular degeneration market consists of sales of anti-vascular endothelial growth factor (anti-VEGF) drugs, photodynamic therapy (PDT), low-vision aids, and telescopic lenses. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Product Code: r11464

1. Executive Summary

2. Age-Related Macular Degeneration Market Characteristics

3. Age-Related Macular Degeneration Market Trends And Strategies

4. Age-Related Macular Degeneration Market - Macro Economic Scenario

4.1. Impact Of High Inflation On the Market
4.2. Ukraine-Russia War Impact On the Market
4.3. COVID-19 Impact On the Market

5. Global Age-Related Macular Degeneration Market Size and Growth

5.1. Global Age-Related Macular Degeneration Market Drivers and Restraints
- 5.1.1. Drivers Of The Market
- 5.1.2. Restraints Of The Market
5.2. Global Age-Related Macular Degeneration Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
5.3. Global Age-Related Macular Degeneration Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Age-Related Macular Degeneration Market Segmentation

6.1. Global Age-Related Macular Degeneration Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Wet Age-Related Macular Degeneration (AMD)
Dry Age-Related Macular Degeneration (AMD)
6.2. Global Age-Related Macular Degeneration Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Eylea
Lucentis
Avastin
Other Products
6.3. Global Age-Related Macular Degeneration Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Intravenous
Intravitreal
6.4. Global Age-Related Macular Degeneration Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Hospital Pharmacy
Specialty Pharmacy
Online Pharmacy

7. Age-Related Macular Degeneration Market Regional And Country Analysis

7.1. Global Age-Related Macular Degeneration Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
7.2. Global Age-Related Macular Degeneration Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Age-Related Macular Degeneration Market

8.1. Asia-Pacific Age-Related Macular Degeneration Market Overview
Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Age-Related Macular Degeneration Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.3. Asia-Pacific Age-Related Macular Degeneration Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.4. Asia-Pacific Age-Related Macular Degeneration Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Age-Related Macular Degeneration Market

9.1. China Age-Related Macular Degeneration Market Overview
9.2. China Age-Related Macular Degeneration Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.3. China Age-Related Macular Degeneration Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.4. China Age-Related Macular Degeneration Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Age-Related Macular Degeneration Market

10.1. India Age-Related Macular Degeneration Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.2. India Age-Related Macular Degeneration Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.3. India Age-Related Macular Degeneration Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Age-Related Macular Degeneration Market

11.1. Japan Age-Related Macular Degeneration Market Overview
11.2. Japan Age-Related Macular Degeneration Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.3. Japan Age-Related Macular Degeneration Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.4. Japan Age-Related Macular Degeneration Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Age-Related Macular Degeneration Market

12.1. Australia Age-Related Macular Degeneration Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.2. Australia Age-Related Macular Degeneration Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.3. Australia Age-Related Macular Degeneration Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Age-Related Macular Degeneration Market

13.1. Indonesia Age-Related Macular Degeneration Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.2. Indonesia Age-Related Macular Degeneration Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.3. Indonesia Age-Related Macular Degeneration Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Age-Related Macular Degeneration Market

14.1. South Korea Age-Related Macular Degeneration Market Overview
14.2. South Korea Age-Related Macular Degeneration Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.3. South Korea Age-Related Macular Degeneration Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.4. South Korea Age-Related Macular Degeneration Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Age-Related Macular Degeneration Market

15.1. Western Europe Age-Related Macular Degeneration Market Overview
15.2. Western Europe Age-Related Macular Degeneration Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.3. Western Europe Age-Related Macular Degeneration Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.4. Western Europe Age-Related Macular Degeneration Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Age-Related Macular Degeneration Market

16.1. UK Age-Related Macular Degeneration Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.2. UK Age-Related Macular Degeneration Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.3. UK Age-Related Macular Degeneration Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Age-Related Macular Degeneration Market

17.1. Germany Age-Related Macular Degeneration Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.2. Germany Age-Related Macular Degeneration Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.3. Germany Age-Related Macular Degeneration Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Age-Related Macular Degeneration Market

18.1. France Age-Related Macular Degeneration Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.2. France Age-Related Macular Degeneration Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.3. France Age-Related Macular Degeneration Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Age-Related Macular Degeneration Market

19.1. Italy Age-Related Macular Degeneration Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.2. Italy Age-Related Macular Degeneration Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.3. Italy Age-Related Macular Degeneration Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Age-Related Macular Degeneration Market

20.1. Spain Age-Related Macular Degeneration Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.2. Spain Age-Related Macular Degeneration Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.3. Spain Age-Related Macular Degeneration Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Age-Related Macular Degeneration Market

21.1. Eastern Europe Age-Related Macular Degeneration Market Overview
21.2. Eastern Europe Age-Related Macular Degeneration Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.3. Eastern Europe Age-Related Macular Degeneration Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.4. Eastern Europe Age-Related Macular Degeneration Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Age-Related Macular Degeneration Market

22.1. Russia Age-Related Macular Degeneration Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.2. Russia Age-Related Macular Degeneration Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.3. Russia Age-Related Macular Degeneration Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Age-Related Macular Degeneration Market

23.1. North America Age-Related Macular Degeneration Market Overview
23.2. North America Age-Related Macular Degeneration Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.3. North America Age-Related Macular Degeneration Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.4. North America Age-Related Macular Degeneration Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Age-Related Macular Degeneration Market

24.1. USA Age-Related Macular Degeneration Market Overview
24.2. USA Age-Related Macular Degeneration Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.3. USA Age-Related Macular Degeneration Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.4. USA Age-Related Macular Degeneration Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Age-Related Macular Degeneration Market

25.1. Canada Age-Related Macular Degeneration Market Overview
25.2. Canada Age-Related Macular Degeneration Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.3. Canada Age-Related Macular Degeneration Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.4. Canada Age-Related Macular Degeneration Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Age-Related Macular Degeneration Market

26.1. South America Age-Related Macular Degeneration Market Overview
26.2. South America Age-Related Macular Degeneration Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.3. South America Age-Related Macular Degeneration Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.4. South America Age-Related Macular Degeneration Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Age-Related Macular Degeneration Market

27.1. Brazil Age-Related Macular Degeneration Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.2. Brazil Age-Related Macular Degeneration Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.3. Brazil Age-Related Macular Degeneration Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Age-Related Macular Degeneration Market

28.1. Middle East Age-Related Macular Degeneration Market Overview
28.2. Middle East Age-Related Macular Degeneration Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.3. Middle East Age-Related Macular Degeneration Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.4. Middle East Age-Related Macular Degeneration Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Age-Related Macular Degeneration Market

29.1. Africa Age-Related Macular Degeneration Market Overview
29.2. Africa Age-Related Macular Degeneration Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.3. Africa Age-Related Macular Degeneration Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.4. Africa Age-Related Macular Degeneration Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Age-Related Macular Degeneration Market Competitive Landscape And Company Profiles

30.1. Age-Related Macular Degeneration Market Competitive Landscape
30.2. Age-Related Macular Degeneration Market Company Profiles
- 30.2.1. F. Hoffmann-La Roche Ltd.
  - 30.2.1.1. Overview
  - 30.2.1.2. Products and Services
  - 30.2.1.3. Strategy
  - 30.2.1.4. Financial Performance
- 30.2.2. Novartis AG
  - 30.2.2.1. Overview
  - 30.2.2.2. Products and Services
  - 30.2.2.3. Strategy
  - 30.2.2.4. Financial Performance
- 30.2.3. Bayer AG
  - 30.2.3.1. Overview
  - 30.2.3.2. Products and Services
  - 30.2.3.3. Strategy
  - 30.2.3.4. Financial Performance
- 30.2.4. Pfizer Inc.
  - 30.2.4.1. Overview
  - 30.2.4.2. Products and Services
  - 30.2.4.3. Strategy
  - 30.2.4.4. Financial Performance
- 30.2.5. Bausch Health Companies Inc.
  - 30.2.5.1. Overview
  - 30.2.5.2. Products and Services
  - 30.2.5.3. Strategy
  - 30.2.5.4. Financial Performance

31. Global Age-Related Macular Degeneration Market Competitive Benchmarking

32. Global Age-Related Macular Degeneration Market Competitive Dashboard

33. Key Mergers And Acquisitions In The Age-Related Macular Degeneration Market

34. Age-Related Macular Degeneration Market Future Outlook and Potential Analysis

34.1 Age-Related Macular Degeneration Market In 2028 - Countries Offering Most New Opportunities
34.2 Age-Related Macular Degeneration Market In 2028 - Segments Offering Most New Opportunities
34.3 Age-Related Macular Degeneration Market In 2028 - Growth Strategies
- 34.3.1 Market Trend Based Strategies
- 34.3.2 Competitor Strategies

35. Appendix

35.1. Abbreviations
35.2. Currencies
35.3. Historic And Forecast Inflation Rates
35.4. Research Inquiries
35.5. The Business Research Company
35.6. Copyright And Disclaimer